Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.
The company applies AI to optimize molecules across discovery and production with aims to contribute to the rebuilding of U.S.-based drug innovation and manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results